Areas of Focus
- Development of new drugs targeting protein degraders
- Development of new allosteric inhibitors
Work Experience
- 2021-03~Present - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Researcher, Group Leader
- 2017-07~2020-11 - University of Michigan, Ann Arbor - Postdoctoral Researcher
- 2011-05~2013-09 - GlaxoSmithKline Shanghai R&D Center - Medicinal Chemist
- 2006-07~2011-05 - Shanghai ChemPartner Co., Ltd. - Senior Organic Synthesis Researcher, Group Leader
Academic Background & Achievements
- 2013-09--2017-06 Ph.D.: Fudan University
- 2004-09--2006-06 Master's Degree: Wuhan University
- 1999-09--2003-06 Bachelor's Degree: Wuhan Institute of Technology
Publications
- Discovery of a Covalent Inhibitor Selectively Targeting the Autophosphorylation Site of c-Src Kinase, 10th Author, 2024
- Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity Against AR Mutants for the Treatment of AR+ Human Prostate Cancer, 9th Author, 2023
- Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity, 6th Author, 2023
- Discovery of PVD-06 as a Subtype-Selective and Efficient PTPN2 Degrader, 10th Author, Corresponding Author, 2023
- E3 ligase ligand optimization of Clinical PROTACs, 11th Author, 2023
- (-)-Epigallocatechin Gallate is a Noncompetitive Inhibitor of NAD Kinase, 7th Author, 2022
- The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay, 11th Author, 2022
- Metal-free photo-induced sulfidation of aryl iodide and other chalcogenation, 11th Author, 2022
- Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1, 5th Author, 2022
- Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer, 12th Author, 2022
- Intramolecular N-Me and N-H Aminoetherification for the Synthesis of N-Unprotected 3-Amino-O-Heterocycles, 2nd Author, 2021
- Pharmacological inhibition of SRC-1 phase separation suppresses YAP oncogenic transcription activity, 4th Author, 2021
- Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein, 1st Author, 2020
- Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER), 3rd Author, 2019
- Effective approach to ureas through organocatalyzed one-pot process, 1st Author, 2018
- Discovery of novel 1,2,3,4-tetrahydrobenzo4, 5thieno2, 3-cpyridine derivatives as potent and selective CYP17 inhibitors, 1st Author, 2017
- Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment, 4th Author, 2017
- Divergent copper-mediated dimerization and hydroxylation of benzamides involving C-H bond functionalization, 1st Author, 2016
- Fluorination of 2-substituted benzo[b]furans with Selectfluor, 1st Author, 2015
